Tagged with clinic

LatAm A vibrant and diverse continent, home to over 650 million people and the highest life expectancy among developing regions, Latin America is now emerging as a globally relevant life sciences investment destination. LatAm has a robust heritage of scientific achievement – Bernardo Houssay (1947) and César Milstein (1984) of Argentina…

USA Sanskriti Thakur of decentralised clinical trial platform provider Medable, writing in the May 2023 edition of DIA’s Global Forum magazine, argues for an urgent rethink of clinical research to better include a more diverse patient population and protect women, mothers, families, and society at large.   This Mother’s Day, women…

Belgium Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the company’s biosimilar portfolio has the potential to contribute to significant savings for the healthcare system.   Improving the evaluation process…

Greece Managing Director of MSD Greece, Cyprus & Malta Agata Jakoncic, who also serves as president of Greece’s PhRMA Innovation Forum (PIF), draws on her three decades of industry experience to outline some of the key challenges in the Greek pharma market today which threaten its sustainability and the ability of…

Greece Yvoni Papastelatou outlines Sanofi’s commitment to Greece, where the multinational firm has a strong and diverse team, a burgeoning clinical trial footprint, and is rolling out the global ‘play to win’ strategy, with a common ambition to leverage science and innovation. She also touches on the access challenges in the…

Belgium Eli Lilly Belgium’s Frederic Clais discusses the potential impact of upcoming reform of the country’s access and reimbursement system, the country’s enduring relevance to the company as home to its European Clinical Trial Services (ELECTS) division, and his aim to reach 200,000 patients in Belgium with Lilly treatments before the…

Belgium Novartis is one of Belgian pharma’s biggest investors across manufacturing and R&D, contributing EUR 598.9 million to GDP in 2022, creating 4,403 direct and indirect jobs, and reaching 5,349,628 million patients via its locally available portfolio. 18 months into his role as Country President for BeLux, Federico Mambretti expands on…

Greece EY Greece’s George Mitropoulos outlines some of the key challenges and opportunities for both local manufacturers and multinational innovators in Greece, how EY is uniquely positioned to assist them, and the fundamentals that give him cause for optimism for both the Greek economy and its healthcare sector.   We believe…

Belgium After a 25-year-long career at Roche, spent at local affiliates in Switzerland, Germany, and the Netherlands, as well as in global positions in Switzerland and the US, Marie-José Borst took on the role of GM at the firm’s BeLux affiliate. Having spent a year on the job, she explains some…

Ukraine Igor Bondarenko of Ukraine’s Dnipro State Medical University, Evgeny Levenko from clinical trials company, ARENSIA, and Olena Popova from IQVIA offer their perspectives on maintaining quality and ensuring participant protection in clinical trials in Ukraine during wartime.   The ongoing war places unprecedented pressure on the healthcare system and clinical…

Belgium Belgium, with a total of EUR 5.5 billion in R&D spending in 2021, is the country with the fourth largest research expenditure in the EU and the first per inhabitant.  As a recent study from Deloitte sponsored by the Belgian pharmaceutical industry association, pharma.be, shows, Belgium is also a leader…

Ukraine The March edition of DIA’s Global Forum magazine features a special section on clinical research in Ukraine, over one year on from the beginning of the Russian invasion. Here, Chieko Kurihara of Kanagawa Dental University, Japan; Victoriia Dobrova of Ukraine’s National University of Pharmacy; Francis P. Crawley of the Good…